Ftse Mib
35.090,23
-0,64%
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
94.347,82
-0,38%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mustang Bio Inc (MBIO) Mustang Bio Inc (MBIO) Notizie

MBIO

Mustang Bio (MBIO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MBIO
DataOraFonteTitoloSimboloCompagnia
10/01/202523:09Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:MBIOMustang Bio Inc
10/01/202523:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
06/12/202423:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBIOMustang Bio Inc
02/12/202422:45Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
29/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBIOMustang Bio Inc
22/11/202422:45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
12/11/202414:30GlobeNewswire Inc.Mustang Bio Receives Positive Listing Determination from NasdaqNASDAQ:MBIOMustang Bio Inc
08/11/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBIOMustang Bio Inc
07/11/202414:30GlobeNewswire Inc.Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaNASDAQ:MBIOMustang Bio Inc
29/10/202421:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
24/10/202420:10GlobeNewswire Inc.Mustang Bio Announces Exercise of Warrants for $4 Million Gross ProceedsNASDAQ:MBIOMustang Bio Inc
16/08/202423:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
19/07/202423:26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
10/07/202422:41Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:MBIOMustang Bio Inc
21/06/202422:01GlobeNewswire Inc.Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
20/06/202414:00GlobeNewswire Inc.Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
17/06/202414:30GlobeNewswire Inc.Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T TherapyNASDAQ:MBIOMustang Bio Inc
05/06/202402:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
02/05/202422:01GlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
30/04/202402:00GlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
28/03/202414:00GlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
11/03/202421:05GlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
11/03/202421:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
07/03/202413:30GlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
11/01/202414:30GlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
11/12/202314:30GlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
14/11/202322:05GlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
03/11/202320:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
02/11/202314:28GlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
30/10/202319:15GlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MBIO

La tua Cronologia

AQEU
SWP
Sodexo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network